Pharmaceutical compositions of 5-ht6 antagonist

An immediate release pharmaceutical composition on a total of 100% by weight comprises:

• a) from about 2% to about 60% 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl) methyl]-1H-indole or a pharmaceutically acceptable salt thereof;
• b) from about 36% to about 97% diluent or total of two diluents;
• wherein the diluent is selected from the group consisting of microcrystalline cellulose, lactose monohydrate, dibasic calcium phosphate, lactose, lactose hydrate, lactose anhydrate, mannitol, starch and isomalt;
• c) from about 0.5% to about 2% lubricant;
• wherein the lubricant is magnesium stearate;
• d) from about 0.5% to about 1% glidant;
• wherein the glidant is colloidal silicon dioxide;
• e) 0% to about 10% binder;
• wherein the binder is selected from group consisting of povidone or hydroxypropyl methylcellulose;
• f) 0% to about 5% disintegrant;
• wherein the disintegrant is selected from crospovidone, sodium starch glycolate and croscarmellose sodium;
• and
• g) 0% to about 2% acidifying agent;
• wherein the acidifying agent is citric acid.